IBA - PanTera signs supply agreement with Bayer
PanTera signed an agreement with Bayer for the supply of Actinium-225. This is the first agreement signed with a major drug developer and we hope to see others coming in. It demonstrates the reliability and credibility of PanTera as Act-225 supplier.The agreement currently only covers the supply for clinical trial needs but we could envision it to be upgraded to a commercial deal down the line as well. No financial details disclosed.News on the Act-225 project are one of the 5 main drivers we see for the share price in the next 12 months. Buy and TP reiterated.IBA- Ion Beam Applications develops and markets technologies and pharmaceutical products for the healthcare sector, with a focus on cancer diagnosis and therapy. Co. is also engaged in the sterilization and ionization market. Co. operates in two primary business segments: Equipment and Pharmaceuticals. Co.'s Equipment segment encompasses development, fabrication, and services associated with medical and industrial particle accelerators, proton therapy systems, and a range of dosimetry products, while Co.'s Pharmaceuticals segment encompasses the production and distribution of radiopharmaceutical agents as well as its bioassay operations.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.